Tags : VARSITY

Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study

Tuba Khan May 20, 2019

Shots: The P-III VARSITY study results involves assessing of Entyvio (vedolizumab,IV) vs Humira (adalimumab,SC) in 769 patients with moderate to severely active ulcerative colitis for 52wks. The P-III VARSITY study […]readmore

Tags : VARSITY

Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : VARSITY

﻿Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Takeda Reports Results of Entyvio (vedolizumab) in P-III VARSITY Study